The document summarizes recent and ongoing policy trends and initiatives related to the opioid epidemic, including expansion of medication-assisted treatment (MAT), increased access to naloxone, implementation of prescription drug monitoring programs (PDMPs), and efforts to improve prescriber education and impose quantity limits on opioid prescriptions. Key pieces of legislation discussed are the Comprehensive Addiction and Recovery Act (CARA) and the Mental Health Parity and Addiction Equity Act. The document also outlines state policies on naloxone access laws, good Samaritan laws, and prescription limits.
Virginia AFP's lobbyist Hunter Jamerson's presentation from the 2013 SLC on the unique Medicaid reform approach being followed in the state of Virginia.
Virginia AFP's lobbyist Hunter Jamerson's presentation from the 2013 SLC on the unique Medicaid reform approach being followed in the state of Virginia.
The Patient-Centered Medical Home in the Transformation From Healthcare to He...Paul Grundy
Surgeon General of the Navy VADM Matthew L. Nathan, MC USN
Fortunately, we have a way to address this crisis—the
Patient-Centered Medical Home (PCMH) model launched at Naval Hospital Pensacola and Walter Reed National Military Medical Center, Bethesda, Maryland (formerly the National Naval Medical Center) in 2008. It is now being implemented throughout the Military Health System (MHS) and carries great promise. It provides the clinical framework we need to meet our strategic objectives in terms of quality of care, impact on costs, population health, and readiness. One of the most significant benefits of the team-based, collaborative approach is that it allows us to embed within a primary care environment the psychologists, nutritionists, tobacco cessation specialists, mind-body medicine therapists, and health educators our patients need in order to develop and maintain mindful, healthy behaviors—along with the “mental armor,” our active duty military personnel need to increase their operational effectiveness and their resiliency in bouncing back from stressful situations. As we move ahead with this more comprehensive approach to health, we can begin to better address so many of our patients for whom we can find no specific reason for pain and discomfort. The PCMH model also provides a positive impact on our costs. Early data reporting from the PCMH clinics at Bethesda show reduced visits to the emergency room, lowered pharmacy costs, and significant per beneficiary per year savings and improved Healthcare Effectiveness Data and Information Set metrics, access, and patient satisfaction and trust. These positive impacts on the bottom line can be applied directly to improved costs or toward the reallocation of resources from reimbursing those who are sick to the population health-based programs that can make and keep our patients healthy.More significant, however, the PCMH environment allows us to go beyond mere collaboration and to a much more proactive approach to managing our patient populations. It is within the context of the medical home that we can begin to surround our patients with the tools and resources they need to move them from health care to health.
National Conference on Health and Domestic Violence. Plenary talk Paul Grundy
explaining how the Patient Centered Medical Home (PCMH) platform for healthcare deliver is more likely to support domestic violence prevention and creat a safer environment than the FFS episode of care system we are in now. The medical Home is a home for the data where the all the data goes and is held accountable this idea was first articulated by Dr. Calvin C.J. Sia, a Honolulu-based pediatrician in 1967.
This concept of the medical home was integrated with Ed Wagners Chronic disease Model and Thomas Bodenheimer Kevin Grumbach advanced/proactive primary care at the request of the Patient Centered Primary care Collaborative into a set of principles Know as the Joint principles of the Patient centered medical home.
The patient-centered medical home (PCMH), is a team based health care delivery set of principles led by a physician that provides comprehensive and continuous medical care to patients with the goal of obtaining maximized health outcomes. It is "an approach to providing comprehensive primary care for children, youth and adults" The provision PCMH medical homes allow better access to health care, increase satisfaction with care, and improve health. Joint principles that define a PCMH have been established through the cohesive efforts of the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Physicians (ACP), and American Osteopathic Association (AOA).[10] Care coordination is an essential component of the PCMH. Care coordination requires additional resources such as health information technology, and appropriately trained staff to provide coordinated care through team-based models. Additionally, payment models that compensate PCMHs for their effort devoted to care coordination activities and patient-centered care management that fall outside the face-to-face patient encounter may help encourage coordination.
Partnering with Patients, Families and Communities for Health: A Global Imper...EngagingPatients
Engagement is an essential tool to improving global health. This report introduces a new framework for engagement to help countries assess current programs and think strategically about future engagement opportunities. It spotlights barriers to engagement and offers concrete examples of effective engagement from around the globe.
The Patient-Centered Medical Home in the Transformation From Healthcare to He...Paul Grundy
Surgeon General of the Navy VADM Matthew L. Nathan, MC USN
Fortunately, we have a way to address this crisis—the
Patient-Centered Medical Home (PCMH) model launched at Naval Hospital Pensacola and Walter Reed National Military Medical Center, Bethesda, Maryland (formerly the National Naval Medical Center) in 2008. It is now being implemented throughout the Military Health System (MHS) and carries great promise. It provides the clinical framework we need to meet our strategic objectives in terms of quality of care, impact on costs, population health, and readiness. One of the most significant benefits of the team-based, collaborative approach is that it allows us to embed within a primary care environment the psychologists, nutritionists, tobacco cessation specialists, mind-body medicine therapists, and health educators our patients need in order to develop and maintain mindful, healthy behaviors—along with the “mental armor,” our active duty military personnel need to increase their operational effectiveness and their resiliency in bouncing back from stressful situations. As we move ahead with this more comprehensive approach to health, we can begin to better address so many of our patients for whom we can find no specific reason for pain and discomfort. The PCMH model also provides a positive impact on our costs. Early data reporting from the PCMH clinics at Bethesda show reduced visits to the emergency room, lowered pharmacy costs, and significant per beneficiary per year savings and improved Healthcare Effectiveness Data and Information Set metrics, access, and patient satisfaction and trust. These positive impacts on the bottom line can be applied directly to improved costs or toward the reallocation of resources from reimbursing those who are sick to the population health-based programs that can make and keep our patients healthy.More significant, however, the PCMH environment allows us to go beyond mere collaboration and to a much more proactive approach to managing our patient populations. It is within the context of the medical home that we can begin to surround our patients with the tools and resources they need to move them from health care to health.
National Conference on Health and Domestic Violence. Plenary talk Paul Grundy
explaining how the Patient Centered Medical Home (PCMH) platform for healthcare deliver is more likely to support domestic violence prevention and creat a safer environment than the FFS episode of care system we are in now. The medical Home is a home for the data where the all the data goes and is held accountable this idea was first articulated by Dr. Calvin C.J. Sia, a Honolulu-based pediatrician in 1967.
This concept of the medical home was integrated with Ed Wagners Chronic disease Model and Thomas Bodenheimer Kevin Grumbach advanced/proactive primary care at the request of the Patient Centered Primary care Collaborative into a set of principles Know as the Joint principles of the Patient centered medical home.
The patient-centered medical home (PCMH), is a team based health care delivery set of principles led by a physician that provides comprehensive and continuous medical care to patients with the goal of obtaining maximized health outcomes. It is "an approach to providing comprehensive primary care for children, youth and adults" The provision PCMH medical homes allow better access to health care, increase satisfaction with care, and improve health. Joint principles that define a PCMH have been established through the cohesive efforts of the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Physicians (ACP), and American Osteopathic Association (AOA).[10] Care coordination is an essential component of the PCMH. Care coordination requires additional resources such as health information technology, and appropriately trained staff to provide coordinated care through team-based models. Additionally, payment models that compensate PCMHs for their effort devoted to care coordination activities and patient-centered care management that fall outside the face-to-face patient encounter may help encourage coordination.
Partnering with Patients, Families and Communities for Health: A Global Imper...EngagingPatients
Engagement is an essential tool to improving global health. This report introduces a new framework for engagement to help countries assess current programs and think strategically about future engagement opportunities. It spotlights barriers to engagement and offers concrete examples of effective engagement from around the globe.
HEALTH POLICY ANALYSIS 2
HEALTH POLICY ANALYSIS
Student’s Name
Institutional Affiliation
Over the last two decades, the United States of America has experienced an increase in the deaths that result from opioid use disorder. For this reason, there was a need for the American congress to pass policies that would help the nation avert the impending national disaster. In October 2018, the American congress passed a new act that affected the country’s healthcare policies. Support for patients and communities act was passed in response to the opioid epidemic facing the United States of America. The show was developed in conjunction with other related actions to help address the problem of opioid addiction in the United States of America. Drug Addiction Act of 2000 provides a waiver for physicians prescribing drugs that manage opioid use disorder. Before passing the Support for patients and communities act, physicians were supposed to undergo an eight-hour training to be given the waiver to prescribe drugs such as buprenorphine. The Support for Patients and communities act allows graduate physicians to prescribe buprenorphine without restrictions (Shapiro et al., 2019).
One of the policy’s impacts on healthcare is that it provides for improved accessibility to evidence-based addiction treatment. Before the policy was enacted, it was hard for the opioid addicts in the United States of America to access treatment. Healthcare programs such as Medicare and Medicaid have expanded their services to ensure that opioid addicts access treatment plans. Such has made it easy for the American healthcare system to meet its target of improving healthcare access for all Americans (Incze et al., 2021).
Another way that the policy has impacted the American healthcare system is by expanding workforce opportunities. Healthcare facilities depend on other facilities to achieve the overall goal of achieving health among the patients. When the policy was passed, it raised the possibilities for healthcare support by increasing the recovery community centers. Opioid use disorder is an addiction that cannot be healed with a short-term treatment plan—the policy allowed for the building of community centers where opioid-addicted Americans can be treated until they recover. The community centers are essential to decongest the American healthcare facilities while supporting the overall goal of a healthy country. Patients recovering from Opioid addiction are housed in community centers while they undergo treatment before they are allowed to rejoin their respective communities (Jones & McCance-Katz, 2018).
The policy has been applied in healthcare practice by allowing for a capacity increase in emergency overdose response. Before the act was signed into law, many Americans died from an opioid overdose since physicians could not prescribe buprenorphine without mandatory training. Once the policy was enacted, it allowed physicians to prescribe buprenorphine ...
White House Office of National Drug Control Policy on the implications of health reform in substance abuse prevention and treatment.
(Keith Humphreys
Senior Policy Advisor, White House ONDCP)
BRP Pharmaceuticals Physician dispensing services enables doctors and clinics to offer their patients timely, convenient, and hassle-free alternatives for receiving their medication. Visit: http://www.brppharma.com/
A new study adds further evidence to suggest that opioid prescribing in the U.S. is skewed and concentrated among a few providers. Researchers looked at prescribing patterns in data from an unspecified national private insurer between 2003-2017.
Around 670,000 providers prescribed more than 8 million standard doses of opioid prescriptions — but more than a quarter of these prescriptions were written by only 1% of physicians. And in 2017, these physicians prescribed nearly half of all the dispensed opioids. This small group of doctors also prescribed higher doses than recommended, and for longer durations than guidelines allow.
What’s encouraging, the authors suggest, is that the vast majority of physicians do seem to follow guidelines. Some caveats: The study was based on one company’s data, and didn’t look at medical reasons behind prescriptions.
Office-Based Opioid Treatment: What You Need to Know: Trends in Behavioral He...Epstein Becker Green
Presented by David Shillcutt (Associate, Epstein Becker Green) and Kristina Sherry (Attorney, Nelson Hardiman) on April 4, 2019.
Office-based opioid treatment providers are on the front lines of the response to the opioid epidemic, but recent developments in federal and state legislation have significant implications for provider business models and service delivery strategies.
This webinar will examine provider capacity issues for medication assisted treatment, the opportunities and challenges of telemedicine for addiction services, and the expansion of innovative service delivery networks including the “Hub and Spoke” system and related models.
Part of a "first Thursdays" webinar series hosted by Behavioral Health Association of Providers, Epstein Becker & Green, P.C., and Nelson Hardiman, LLP.
More info: https://www.ebglaw.com/events/office-based-opioid-treatment-what-you-need-to-know-trends-in-behavioral-health-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
Biomedical Informatics project for implementing a state wide screening program for narcotic seeking patients. Project defined from abstract to specific implementation and measurement criteria.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
3. Source: Park H and Bloch M. How the Epidemic of Drug Overdose Deaths Ripples Across America. The
New York Times. Jan 19, 2016. http://www.nytimes.com/interactive/2016/01/07/us/drug-
overdose-deaths-in-the-us.html Accessed October 3, 2016.
5. ComprehensiveAddiction and RecoveryAct (CARA)
Expands DATA 2000 prescribing privileges to NPs and PAs
Requires updates to 8-hour course andTIP 40
Allows states to add training requirements and lower patient limit
Administrative rule increases patient limit to 275
Qualify via board certification or practice setting
Annual reporting requirements & 3-year renewal
Grants to fund treatment
6.
7. CARA
Sec. 107:Grants to FQHCs,OTPs, DATA 2000-waived practitioners to
support naloxone co-prescribing to patient or caregiver ($5m through
2021)
Sec. 110:Grants to states to implement standing orders & encourage
pharmacies to dispense naloxone, develop training materials & education
public ($5m through 2019)
House JudiciaryCommittee Hearing: Treating the Opioid Epidemic:
The State of Competition in the Markets for Addiction Medicine
(Sept. 2016)
FDA AdvisoryCommittee (Oct. 2016)
8. Source: National Conference of State Legislatures. Drug Overdose Immunity and Good Samaritan
Laws. August 1, 2016. http://www.ncsl.org/research/civil-and-criminal-justice/drug-overdose-
immunity-good-samaritan-laws.aspx Accessed October 3, 2016.
NaloxoneAccess laws may give immunity
to prescribers, dispensers and/or lay
administrators acting in good faith; allow
for layperson distribution and possession
w/o Rx; and/or allow for third-party
prescribing or standing orders.
Good Samaritan laws may give immunity
for bystanders from possession of a
controlled substance and/or drug
paraphernalia, as well as other offenses
such as probation or parole violations.
9. Mental Health Parity andAddiction EquityAct (2008)
White HouseTask Force
Recommendations due Oct. 31
Legislation
Mental Health Reform (H.R. 2646/S. 2680)
Behavioral HealthTransparencyAct (H.R. 4276/S. 2647)
10. Source: ParityTrack. Parity Implementation National Survey. Available at:
https://www.paritytrack.org/reports Accessed: October 18, 2016.
11. CARA
Sec. 109: NASPER Reauthorization allows funds to be used to maintain
existing PDMP, improve integration with prescriber workflow; requires
plan for achieving interoperability with HIT systems, facilitation of
prescriber use ($10m/year through 2021)
12.
13. CDC Guideline
Surgeon General “Turn theTide”
Campaign & Report
FDA Opioids Action Plan
• “Black Box” warning on opioids,
benzodiazepines
• ER/LA REMS Update
• CARA Sec. 106: Requires HHS Secretary to
develop recommendations regarding
prescriber education on opioids
VA/DOD Guideline update
14. Source: Federation of State Medical Boards. Continuing Medical Education Board-by-Board Overview.
Available at:
https://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/GRPOL_CME_Overview_by_State.pdf
State Details
CA 12 hrs before second license
renewal or w/in 4 years
FL Pain mgmt. clinics only
IA 2 hrs every 5 years (primary care
only)
KY 4.5 hrs every 3 years on PDMP,
pain mgmt. or addiction
MD 1 hr on opioid prescribing
MA 3 hrs every 2 years
NC 1 hr
NH 3 hrs for initial licensure + every
2 years
State Details
NV 2 hrs every other 2 yr cycle
NM 5 hrs every 3 years
OH Pain mgmt. clinics only
OK 1 hr every 2 years
RI 2 hrs – topic optional
SC 2 hrs every 2 years
TN 1 hr every 2 years
TX Pain mgmt. clinics only
VT 1 hr on pain mgmt. + 1 hr on
controlled substances prescribing
WV 3 hrs every 3 years
15. CARA
Sec. 702: Partial Fills of Schedule II Controlled Substances.Allows for
partial fills if requested by patient or prescriber. Remaining portions can be
filled within 30 days.
Sec. 704: Medicare Part D Drug Management Program. Allows
Prescription Drug Plans (PDPs) to establish patient review and restriction
programs (“lock-in” programs) for beneficiaries considered at risk of
prescription drug misuse.
16. Source: K.Murphy, M.Becker, J.Locke, C.Kelleher, J.McLeod, and F.Isasi, Finding Solutions to the
Prescription Opioid and Heroin Crisis: A Road Map for States (Washington, D.C.: National Governors
Association Center for Best Practices, July 2016).
State Type Prescription Limits
Connecticut Statute 7-day limit for new opioid prescriptions for adults and all
opioid prescriptions for minors. Exceptions for chronic and
cancer pain, palliative care and clinical judgment.
Illinois Statute Schedule II prescriptions limited to 30-day supply, with
exceptions. Permits multiple prescriptions up to a 90-day
supply if the prescriber meets specified conditions.
Kentucky Board rules required
by statute
48-hour limit on dispensing of Schedule II and III controlled
substances by physicians. No limit on opioid prescriptions.
Massachusetts Statute 7-day limit for new opioid prescriptions for adults and all
opioid prescriptions for minors. Exceptions for chronic and
cancer pain, palliative care and clinical judgment.
Washington Guideline and board
rules required by
statute
Pain specialist consultation required prior to prescribing
daily morphine equivalent doses of 120 mg or greater, with
exceptions.
4,200 members
Founded 1954
Membership composed of a mix of specialties: 1/3 psychiatry, 1/3 primary care, 1/3 other specialties (OB/GYN, pediatrics, emergency medicine, etc)
Addiction medicine recently recognized as a multispecialty subspecialty under ABPM.
We hope and are planning for the first ABMS exam to be held next year, although it hasn’t been announced
There will be a 5-year period following the first exam when ABMS-boarded physicians can sit for the exam without going through a fellowship first
2014
More than 28,000 opioid-related overdose deaths (Rx 18,893 and heroin 10, 574).
Treatment gap:
In 2015, 2.0 million people reported having a pain reliever use disorder and 822,000 people received treatment for the misuse of pain relievers
Over half of the nation’s counties did not have a health provider with the ability to prescribe the medication.
Letter last month in JAMA Psychiatry found:
Medicare beneficiaries had the highest and most rapidly growing rate of “opioid use disorder.”
The data showed the number of doctors who prescribed buprenorphine-naloxone equaled less than 2 percent of the 381,575 prescribers responsible for 56,516,854 Schedule II opioid claims. For instance, the researchers found that for every 40 family physicians prescribing pain killers, only one family physician prescribed the addiction management drug.
Overview of policy trends at federal and state level
Policies can be categorized in two buckets: treatment (demand reduction) and prevention (supply reduction)
Both Congress and the Obama Administration have made efforts to increase access to medication-assisted treatment.
This summer, Congress passed CARA (P.L. 114-198): signed July 2016
First addiction-related bill to receive Senate floor time in decades
MAT-related provisions include:
Expansion of prescribing privileges to NPs and PAs – requires 24 hours of training. SAMSHA working on implementation.
Update to 8-hour buprenorphine waiver course and TIP 40
Allows state to add training requirements and lower the patient limit
For its part, the Administration included MAT as one of its three priorities to combat the opioid epidemic. (We’ll talk about the other two – naloxone access and prescriber education – shortly)
In June, HHS issued a final rule to raise the buprenorphine patient limit to 275
Physicians must be board-certified or work in a qualified practice setting
Requires annual reporting and renewal of waiver every three years
At least 1200 physicians have received waivers to treat up to 275 patients
HHS is also using its funding authority to increase treatment access
March 2016: $94 million to 271 health centers in 45 states; administered by HRSA; expected to help awardees hire approximately 800 providers to treat nearly 124,000 new patients
Aug 2016: $53 million in funding to 44 States, four tribes and DC; administered by SAMHSA and CDC; support 6 programs, including Medication-Assisted Treatment Prescription Drug Opioid Addiction Grants to provide up to $11 million to 11 states to expand access to MAT services. Awardees are Alaska, Arizona, Colorado, Connecticut, Illinois, Louisiana, New Hampshire, North Carolina, Oklahoma, Oregon, and Rhode Island. (SAMHSA).
Laws/regulations to address treatment quality and diversion
MA (2014) Chapter 258 of the Acts of 2014, “An Act to Increase Opportunities for Long Term Substance Abuse Recovery” - requires that all corporate entities treating more than 300 patients for opioid dependency in the form of agonist therapy obtain a license from the Department of Public Health
WV SB 454 (March 2016) – establishes licensing requirements for medication-assisted treatment facilities
TN SB 829 (April 2016) - requires all nonresidential substitution-based treatment centers for opiate addiction to obtain a certificate of need by July 1, 2016, including those on the premises of a physician's office
GA SB 402 (April 2016) - provides for a moratorium on the issuance of new licenses to opioid treatment programs
PA HB 2330 (introduced Sept 2016) – restricts buprenorphine access to opioid treatment programs
CARA Sec. 107: Grant funds could be used to: (1) establish a program for prescribing a drug or device for overdose reversal; (2) train and provide resources for health care providers and pharmacists on the prescribing of overdose reversal drugs or devices; (3) purchase overdose reversal drugs or devices for distribution; (4) offset the co-payments and other cost sharing associated with overdose reversal drugs or devices; and (5) establish protocols to connect patients who have experienced a drug overdose with appropriate treatment, including medication-assisted treatment and appropriate counseling and behavioral therapies.
CARA Sec 110: In this grant program, the Secretary of HHS would award grants to States to: (1) implement strategies for pharmacists to dispense an opioid overdose reversal drug or device pursuant to a standing order; (2) encourage pharmacies to dispense opioid overdose reversal medication pursuant to a standing order; (3) develop or provide training materials on the administration of an opioid overdose reversal drug or device; and (4) educate the public concerning the availability of overdose reversal drugs or devices. A grant may be awarded only if the State involved has authorized standing orders to be issued for overdose reversal drugs or devices.
Aug 2016: The Prescription Drug Opioid Overdose Prevention Grants will provide up to $11 million to 12 states to reduce opioid overdose-related deaths. Funding will support training on prevention of opioid overdose-related deaths as well as the purchase and distribution of naloxone to first responders. Awardees are Alaska, Arkansas, Illinois, Missouri, New Jersey, New Mexico, Oklahoma, South Carolina, Washington, West Virginia, Wisconsin, and Wyoming. (SAMHSA)
Naloxone access laws may give immunity to prescribers, dispensers and/or lay administrators acting in good faith; allow for layperson distribution and possession without a prescription; and/or allow for third-party prescribing or standing orders.
Good Samaritan laws may give immunity for bystanders from possession of a controlled substance and/or drug paraphernalia as well as other offenses such as probation or parole violations.
New Mexico became the first state to enact legislation to increase access to Naloxone in 2001. By June 22, 2016, all but three states (KS, MT, WY) had passed legislation designed to improve layperson naloxone access. Also as of June 22, 2016, 37 states and the District of Columbia have enacted some form of a Good Samaritan or 911 drug immunity law. These laws generally provide immunity from supervision violations and low level drug possession and use offenses when a person who is either experiencing or observing an opiate-related overdose calls 911 for assistance or otherwise seeks medical attention for themselves or another.
Network for Public Health Law is good resource for various laws: https://www.networkforphl.org/_asset/qz5pvn/network-naloxone-10-4.pdf
Mental Health Reform
The House voted overwhelmingly (422-2) to pass H.R. 2646, the Helping Families in Mental Health Crisis Act of 2016 on July 6, 2016.
Requires federal agencies to collaborate to improve compliance with the mental health parity law, to report on federal parity investigations and to create a plan to improve federal parity enforcement. Requires a Government Accountability Office (GAO) study on mental health insurance parity.
S. 2680 - Requires audits of plans that have five or more parity violations and reports to Congress on the result of completed federal parity investigations. Requires additional federal guidance to help plans comply with the parity law. Requires a federal action plan to enhance parity enforcement and a GAO parity study
Behavioral Health Coverage Transparency Act of 2015
This bill amends the Public Health Service Act, Employee Retirement Income Security Act of 1974 (ERISA), and Internal Revenue Code to direct the Departments of Health and Human Services (HHS), Labor, and the Treasury to require group health plans and health insurers to disclose the analyses performed to ensure compliance of plans or coverage with the law and regulations. Disclosures must include findings and conclusions regarding whether non-quantitative treatment limitations (e.g., tiered benefits, step therapy, or preauthorization) applied to mental health or substance use disorder benefits are comparable to, and applied no more stringently than, such limitations on medical and surgical benefits.
HHS, Labor, and Treasury must: (1) issue guidance on the process for current and potential participants and beneficiaries to file formal complaints of plans or insurers being in violation of the requirement for parity between mental health and substance use disorder benefits and medical and surgical benefits, (2) conduct audits of plans and insurers to determine compliance with parity requirements and publish information from those audits, and (House bill) (3) publish information on denials of claims by plans and insurers for mental health and substance use disorder services compared to denials of claims for medical and surgical services.
HHS must establish a consumer parity portal website that allows for submission of complaints and provides information to consumers on parity.
The Government Accountability Office must report on HHS, Labor, and Treasury efforts to enforce parity.
(Senate bill) State health insurance commissioners must report on compliance of plans and insurers with parity requirements and include a comparison of benefits.
ParityTrack has:
Analysis of current legislation, regulatory actions and litigation by state
A model bill that addresses some of the most critical issues in parity at basic levels, including regulatory agency accountability, health benefit plan transparency, definitional clarity for mental health conditions and substance use disorders, consumer and provider education, and coverage for medications that address the opioid crisis. (http://scattergoodfoundation.org/sites/default/files/StateParityLegislation.pdf)
Coalitions working on legislation in: Pennsylvania, Ohio, Tennessee, NJ, Connecticut
Examples:
Illinois: HB1 became law in Sept. 2015 (after a veto override by the General Assembly). It has several sections related to parity:
Makes clear that medical necessity reviews for substance use disorder services cannot use any other criteria besides those put forth by the American Society of Addiction Medicine (ASAM).
Requires plans to make medical necessity criteria for behavioral health treatment available to enrollees and provide a reason for coverage denials within a reasonable amount of time.
Extends the state parity law so that it applies to individual plans.
Requires plans to cover opioid antagonists (like naloxone), if a plan covers prescription medications.
Requires plans to make their prescription medication formularies for substance use disorder medications “no less favorable” than those in place for other medications.
Requires all Illinois Medicaid plans to cover opioid antagonists and other prescription FDA-approved medications for treating substance use disorders.
Requires the Illinois Department of Insurance to enforce the state parity law and the Federal Parity Law by:
Proactively looking for parity violations
Actively responding to consumer and provider complaints
Taking appropriate regulatory action when parity violations are found
Requires the Illinois Department of Insurance to develop a consumer and provider education program about parity that will include live trainings and webinars.
Requires the Illinois Department of Insurance to develop a parity hotline for consumers.
Requires Illinois Medicaid plans to cover any prescription medications for substance use disorders and that there cannot be any prior authorization required for these medications and that any utilization management has to follow ASAM criteria. It also requires Medicaid coverage for opioid antagonists and requires Medicaid plans to comply with the state parity law
Pennsylvania: Among many other things, HB 2173 from the current legislative session will do the following:
Requires insurers to submit annual reports detailing their compliance with the Federal Parity Law , especially their compliance regarding the use of non-quantitative treatment limitations (NQTLs)
Provides specific detail for how the Insurance Department can implement the Federal Parity Law
Defines behavioral health conditions as they are defined in the most recent versions of the DSM or the ICD
22 of the 49 states with PDMPs now legally mandate prescribers to query the system before writing for controlled substances with recognized potential for abuse or dependence.
In Sept. California Gov. Jerry Brown signed a law requiring prescribers to check the CURES database when prescribing Schedule II-IV medications and every 4 months thereafter. Delayed implementation until 6 months after the database is certified operational.
Policymakers should seriously explore and evaluate more positive approaches, including pay-for-performance, malpractice discounts, or immunity from liability for prescribers who diligently use the systems.
(Haffajee RL et al JAMA Mandatory Use of Prescription Drug Monitoring Programs 2015)
NGA Opioid Road Map includes recommendations to:
Require providers to check the PDMP before prescribing Schedule II, III and IV controlled substances.
Require pharmacists to report to the PDMP within 24 hours.
Examples:
New Hampshire: Prescribers are required to query the PDMP when prescribing Schedule II-IV opioids for a patient’s initial prescription for the management or treatment of pain and at least twice a year thereafter; except when 1) controlled medications are being administered to patients in a health care setting; 2) treating acute pain associated with serious traumatic injury, post-operatively, or with an acute medical condition, with clear objective findings by the practitioner, for no more than 30 days. (Effective September 1, 2016)
New Mexico: Requires practitioners other than veterinarians and pharmacists to obtain and review a PDMP report prior to prescribing or dispensing an opioid for the first time to a patient. It further requires practitioners who continuously prescribes or dispenses a controlled substance, to review a PDMP report and a report form an adjacent state, if the practitioner has access to such a system, no less than once every three months for these patients. (Effective January 1, 2017)
In March, Virginia passed several PDMP-related bills:
Allows prescribers and dispensers to delegate PDMP access authority
Requires prescribers or their delegate to request PDMP information on a patient at the time a new course of treatment is being initiated that includes the prescribing of opioids for more than 14 days.
Requires dispensing information be submitted within 24 hours or the dispenser’s next business day. (effective Jan 2017)
CDC Guideline – webinar series
11/29:Assessment for Opioid Use Disorder and Referral to Evidence-Based Treatment
12/6: Risk Mitigation Strategies: PDMPs, UDT, and Naloxone
12/13: Effective Communication with Patients About Opioid Therapy
Surgeon General is promoting CDC prescribing guidelines through the “Turn the Tide” campaign. Pocket guide pictured here. Report to be issued on November 17.
Aug 2016 - FDA is requiring boxed warnings – the FDA’s strongest warning – and patient-focused Medication Guides for prescription opioid analgesics, opioid-containing cough products, and benzodiazepines – nearly 400 products in total
Prescriber education recommendations must include recommendations on:
Which prescribers should participate in such programs; and
How often participation is necessary
VA/DOD updating its Clinical Practice Guideline on the Management of Opioid Therapy for Chronic pain (issued in 2010)
State CME requirements – updated May 19, 2016
CA – 12 hours before second license renewal or within four years, whichever comes first
FL – limited to pain management clinics
IA – for primary care physicians who treat chronic pain, two hours every five years
KY – 4.5 hours every three year licensing cycle as of 2015. Requirement passed in 2012.
MD – one credit – within current renewal cycle
MA – three hours every two-year licensing cycle
NC – one hour every licensing cycle.
NH – three hours in the area of pain management and addiction disorder or a combination, as a condition for initial licensure and license renewal – every two years.
NV – two hours every other two-year licensing cycle
NM – Between November 1, 2012 and no later than June 30, 2014, all NM medical board licensees who hold a federal drug enforcement administration registration and licensure to prescribe opioids, shall complete no less than five hours
OH – limited to pain management clinics
OK – 1 hour every other year on prescribing, dispensing, and administering of controlled substances
RI - 2 hours on universal precautions, infection control, modes of transmission, bioterrorism, end of life education, palliative care, OHSA, ethics, or pain management
SC - at least two (2) hours must be related to approved procedures for prescribing and monitoring schedules II, III, and IV controlled substances.
TN - at least 1 of 40 on prescribing practices; providers of intractable pain treatment must have specialized CME in pain management
TX – limited to pain management clinics
VT - 1 hour must be on hospice, palliative care, and/or pain management services. For each licensee who holds or has applied for a DEA number, at least 1 CME hour must be on safe and effective prescribing of controlled substances.
WV - Beginning May 1, 2014, unless a physician certifies that he or she has not prescribed, administered, or dispensed a controlled substance during the entire previous reporting period, every physician must complete a minimum of three (3) hours of drug diversion training and best practice prescribing of controlled substances training as a condition of licensure renewal
As of June 23, 2016, four states (Connecticut, Massachusetts, Maine and New York) have established seven-day statutory limitations on opioid prescriptions in certain circumstances, with exceptions. Other states have less restrictive statutory limits on prescribing, or promote safe opioid prescribing and dispensing through regulations and guidelines. The following chart provides examples of several state approaches.
Maine – no patient can be on more than 100 MME
Rhode Island – 30 MME limit